Dawson James Analyst Recommendations & Stock Picks This page lists the most recent publicly-reported stock recommendations and ratings issued by analysts at Dawson James. These ratings and price targets were collected from public media reports and are believed to be accurate, but cannot be verified with 100% certainty. MarketBeat and its parent company are in no way affiliated with or endorsed by Dawson James. Country All Countries United States(NYSE & NASDAQ) United States(All Exchanges) Canada United Kingdom Sector All Sectors Aerospace Auto/Tires/Trucks Basic Materials Business Services Computer and Technology Construction Consumer Discretionary Consumer Goods Consumer Staples Finance Industrial Products Medical Miscellaneous Multi-Sector Conglomerates Oils/Energy Retail/Wholesale Services Transportation Utilities All Market Caps Large Cap ($10B+) Medium Cap ($2B-$10B) Small Cap (<$2B) Market Cap MarketRank™ evaluates a company based on dividend strength, earnings, valuation, analysts forecasts, and more.Available with a MarketBeat All Access SubscriptionMarketRank™Upgrade to All Access to use the All Ranks Filter Media sentiment refers to the percentage of positive news stories versus negative news stories a company has received in the past week.Available with a MarketBeat All Access SubscriptionMedia SentimentUpgrade to All Access to use the All Sentiments Filter Analyst consensus is the average investment recommendation among Wall Street research analysts.Available with a MarketBeat All Access SubscriptionAnalyst ConsensusUpgrade to All Access to use the All Ratings Filter Export to Excel CompanyDateActionBrokerageAnalystRatingPrice TargetImpact on PriceDetailsActionsBYRNByrna Technologies9/27/2023Downgraded byDawson JamesBuy -> NeutralLowXXII22nd Century Group8/15/2023Target Lowered byDawson JamesBuy -> Buy$10.00 -> $7.50LowXXII22nd Century Group7/25/2023Target Lowered byDawson James$15.00 -> $10.00LowBYRNByrna Technologies7/12/2023Target Lowered byDawson James$9.50 -> $7.25LowTOONKartoon Studios7/11/2023Target Lowered byDawson James$12.50 -> $10.00LowXXII22nd Century Group7/3/2023Target Lowered byDawson James$67.50 -> $15.00Low Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. NRXPNRx Pharmaceuticals3/17/2023Reiterated byDawson JamesAnalyst J. KolbertBuyLowGOVXGeoVax Labs3/3/2023Initiated byDawson JamesBuy $4.00LowSMSISmith Micro Software2/28/2023Target Lowered byDawson James$8.30 -> $3.50LowSRNESorrento Therapeutics2/13/2023Downgraded byDawson JamesBuy -> NeutralN/AGNPXGenprex1/30/2023Initiated byDawson JamesBuy $3.00LowZOMZomedica1/6/2023Initiated byDawson JamesAnalyst J. KolbertBuy $6.00N/ACHEKCheck-Cap9/15/2022Downgraded byDawson JamesAnalyst J. KolbertBuy -> NeutralLowBYRNByrna Technologies9/8/2022Target Lowered byDawson James$12.00 -> $9.50LowPRPHProPhase Labs7/21/2022Downgraded byDawson JamesNeutral -> SellLowDYAIDyadic International7/18/2022Downgraded byDawson JamesAnalyst J. KolbertBuy -> NeutralLowBYRNByrna Technologies4/26/2022Initiated byDawson JamesBuy $12.00HighLCTXLineage Cell Therapeutics3/11/2022Reiterated byDawson JamesAnalyst Jason KolbertBuy $6.00N/ASMSISmith Micro Software3/11/2022Target Lowered byDawson JamesBuy$11.40 -> $8.30HighPFIEProfire Energy3/9/2022Target Raised byDawson James$1.65 -> $2.00LowKNWNKnow Labs2/8/2022Initiated byDawson JamesBuy $7.00HighCHEKCheck-Cap2/7/2022Upgraded byDawson JamesNeutral -> BuyHighXXII22nd Century Group1/6/2022Target Raised byDawson JamesAnalyst James McIlreeBuy -> Buy$105.00 -> $127.50N/AVUZIVuzix12/21/2021Initiated byDawson JamesBuy $15.00MediumPRPHProPhase Labs10/13/2021Downgraded byDawson JamesAnalyst J. KolbertBuy -> NeutralMediumPFIEProfire Energy8/5/2021Initiated byDawson JamesAnalyst James McIlreeBuy $1.65HighSMSISmith Micro Software8/5/2021Initiated byDawson JamesBuy $11.10HighAVXLAnavex Life Sciences6/21/2021Target Raised byDawson JamesBuy$19.00 -> $35.00LowCHEKCheck-Cap3/17/2021Reiterated byDawson JamesAnalyst J. KolbertBuy -> Neutral $40.00LowCTXRCitius Pharmaceuticals2/25/2021Reiterated byDawson JamesAnalyst J. KolbertBuy $6.00LowFBIOFortress Biotech2/17/2021Target Raised byDawson JamesBuy$16.00 -> $21.00LowPRPHProPhase Labs1/20/2021Initiated byDawson JamesBuy $25.00HighLCTXLineage Cell Therapeutics10/12/2020Reiterated byDawson JamesBuy $6.00N/ACTXRCitius Pharmaceuticals9/17/2020Reiterated byDawson JamesAnalyst J. KolbertBuyLowDAREDaré Bioscience7/12/2020Reiterated byDawson JamesBuy $3.00HighAVXLAnavex Life Sciences6/8/2020Reiterated byDawson JamesBuy $16.00MediumSRNESorrento Therapeutics5/26/2020Initiated byDawson JamesBuy -> Buy $24.00LowCTSOCytosorbents3/9/2020Reiterated byDawson JamesBuy$15.00 -> $17.00HighDYAIDyadic International2/26/2020Reiterated byDawson JamesAnalyst Jason KolbertBuyHighIMACIMAC1/14/2020Reiterated byDawson JamesAnalyst J. KolbertBuy -> NeutralLowMESOMesoblast12/19/2019Initiated byDawson JamesAnalyst Jason KolbertBuy $14.00LowCHEKCheck-Cap12/5/2019Initiated byDawson JamesBuy $80.00LowDYAIDyadic International10/16/2019Initiated byDawson JamesBuy $14.00LowCTXRCitius Pharmaceuticals9/6/2019Initiated byDawson JamesAnalyst Jason KolbertBuy $7.00N/AFBIOFortress Biotech8/26/2019Initiated byDawson JamesBuy $19.00HighADMAADMA Biologics8/12/2019Downgraded byDawson JamesAnalyst J. KolbertBuy -> Neutral $4.00HighAVXLAnavex Life Sciences7/24/2019Initiated byDawson JamesAnalyst J. KolbertBuy $16.00LowINTTinTEST12/28/2018Reiterated byDawson JamesAnalyst B. SineBuyHighORGSOrgenesis12/20/2018Reiterated byDawson JamesAnalyst C. WertherBuyHighSSNTSilverSun Technologies12/19/2018Reiterated byDawson JamesAnalyst B. SineBuyHighORGSOrgenesis12/20/2018Initiated byDawson JamesBuy -> BuyMediumWYYWidePoint12/3/2018Reiterated byDawson JamesAnalyst B. SineBuyHighWTTWireless Telecom Group12/3/2018Reiterated byDawson JamesAnalyst B. SineBuyLowCNVSCineverse10/22/2018Initiated byDawson JamesAnalyst B. SineBuyLowFRXFennec Pharmaceuticals10/10/2018Reiterated byDawson JamesAnalyst C. WertherBuyN/AFENCFennec Pharmaceuticals10/11/2018Initiated byDawson JamesAnalyst C. WertherBuyHighLUNALuna Innovations10/2/2018Initiated byDawson JamesAnalyst B. SineBuyLowSSKNSTRATA Skin Sciences9/4/2018Initiated byDawson JamesAnalyst R. WassermanBuyHighVERUVeru6/25/2018Reiterated byDawson JamesAnalyst R. WassermanBuyMediumIMVIMV6/19/2018Reiterated byDawson JamesAnalyst C. WertherBuyN/ALVOLiveOne6/4/2018Reiterated byDawson JamesAnalyst B. SineBuyMediumALTAltimmune5/29/2018Reiterated byDawson JamesAnalyst R. WassermanBuyHighACSTAcasti Pharma1/29/2018Reiterated byDawson JamesAnalyst R. WassermanBuyLowCVMCEL-SCI10/16/2017Reiterated byDawson JamesAnalyst R. WassermanNeutralN/APAVMPAVmed9/5/2017Reiterated byDawson JamesAnalyst R. WassermanBuy $10.10HighEPIXESSA Pharma8/3/2017Reiterated byDawson JamesAnalyst R. WassermanBuyHighONTXOnconova Therapeutics7/25/2017Reiterated byDawson JamesAnalyst R. WassermanBuyHighCVMCEL-SCI3/11/2016Reiterated byDawson JamesAnalyst R. WassermanBuyN/AENZEnzo Biochem2/9/2016Reiterated byDawson JamesAnalyst R. WassermanBuyN/ASLNOSoleno Therapeutics5/6/2015Initiated byDawson JamesBuy $952.50N/ACVMCEL-SCI3/2/2015Initiated byDawson JamesBuy $3.00N/AAXGNAxoGen5/14/2014Initiated byDawson JamesBuy $5.00N/ANEONeoGenomics5/14/2014Initiated byDawson JamesBuy $6.00N/AABIOARCA biopharma10/9/2013Initiated byDawson JamesBuy $3.75N/AAGENAgenus3/12/2013Reiterated byDawson JamesBuyN/AMDPediatrix Medical Group3/12/2013Downgraded byDawson JamesBuy -> Neutral $80.00N/AARWRArrowhead Pharmaceuticals2/26/2013Initiated byDawson JamesBuy $4.00N/AATOSAtossa Therapeutics12/20/2012Initiated byDawson JamesOutperform $120.00N/ABMYBristol-Myers Squibb12/12/2012Reiterated byDawson JamesMarket Outperform $51.00N/AAMGNAmgen12/7/2012Initiated byDawson JamesOutperform $91.00N/AGEOThe GEO Group12/4/2012Downgraded byDawson JamesMarket PerformN/ASRPTSarepta Therapeutics11/27/2012Initiated byDawson JamesOutperformN/ARMTIRockwell Medical11/27/2012Initiated byDawson JamesOutperform $132.00N/AAGENAgenus11/27/2012Initiated byDawson JamesOutperformN/ASLSSELLAS Life Sciences Group11/27/2012Initiated byDawson JamesOutperform $150.00N/ACYTKCytokinetics11/27/2012Downgraded byDawson JamesOutperformN/AGALTGalectin Therapeutics7/6/2012Target Lowered byDawson JamesBuy $3.00N/ANFLXNetflix10/28/2011Target Lowered byDawson JamesSell$16.50 -> $7.14N/A MarketBeat Community Rating for Dawson JamesCommunity Ranking: 2.7 out of 5 (2.7 of 5 stars)Outperform Votes: 21,026 (Vote Outperform)Underperform Votes: 17,693 (Vote Underperform)Total Votes: 38,719MarketBeat's community ratings are surveys of what our community members think about Dawson James and other research firms. Vote "Outperform" if you believe Dawson James's recommendations will outperform the S&P 500 over the long term. Vote "Underperform" if you believe Dawson James's recommendations will underperform the S&P 500 over the long term. You may vote once every thirty days. Stock Ratings Reports and Tools Today's Ratings: U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top Rated Stocks: Top Rated Stocks Top Rated Dividend Stocks Top Rated Small-Cap Stocks Top Rated Tech Stocks Most Upgraded Stocks Most Downgraded Stocks Lowest Rated Stocks More Ratings Tools: Stock Ratings by Company Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Ratings for Popular Stocks: Alphabet (Google) Amazon Apple Meta (Facebook) Microsoft Netflix Nvidia Tesla Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.